Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jeffrey Curtis

Pulmonary Disease Ann Arbor, MI Medical Doctor

NPI 1578649018 CMS profile 778283

1500 E Medical Center Dr, 3Rd Floor Taubman Center Recp C, Ann Arbor, MI 48109

Open in the dashboard

General payments

$37,219

24 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$13,250 paid to institutions, not to them · program years 2020–2022

Through program year 2024, Jeffrey Curtis of Ann Arbor, MI is reported in the CMS Open Payments database as having received $37,219 across 24 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $13,250 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $13,105 6
2022 General $451 2
2021 General $2,500 1
2020 General $10,893 4
2019 General $10,270 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Curtis
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Jeffrey Curtis were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Jeffrey Curtis Pulmonary Disease median Middle half National median
2019 $10,270 $377 $109–$1,340 $163
2020 $10,893 $230 $56–$907 $114
2021 $2,500 $269 $68–$1,072 $132
2022 $451 $390 $100–$1,457 $149
2023 $0 $419 $114–$1,659 $160
2024 $13,105 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AstraZeneca UK Limited $18,050 12 payments
  2. Genzyme Corporation $9,704 3 payments
  3. AstraZeneca Pharmaceuticals LP $3,502 4 payments
  4. Genentech USA, Inc. $3,296 2 payments
  5. CSL Behring $2,500 1 payment
  6. Genentech, Inc. $105 1 payment
  7. Novartis Pharmaceuticals Corporation $62 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $23,956 9 payments
  2. Travel and Lodging $10,078 4 payments
  3. Honoraria $2,500 1 payment
  4. Food and Beverage $685 10 payments
Products named General payments · program years 2019–2024
  1. KEVZARA $9,704 3 payments
  2. BREZTRI AEROSPHERE $3,113 3 payments
  3. Zemaira $2,500 1 payment
  4. BREZTRI $389 1 payment
  5. COSENTYX $62 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

24 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record